How cells transport materials from the nucleus to the cytoplasm
Cellular mechanisms of nucleocytoplasmic export through Nuclear Envelope Budding
['FUNDING_R01'] · FRED HUTCHINSON CANCER CENTER · NIH-10876338
This study is looking at how cells move important materials like DNA and proteins from the nucleus to the rest of the cell, focusing on a new way this happens that could help us understand how problems in this process might lead to cancer, which could eventually help patients with better treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10876338 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which cells transport nucleic acids and proteins from the nucleus to the cytoplasm, a process crucial for cell function. It focuses on a newly discovered pathway called Nuclear Envelope (NE) budding, which allows large macromolecular complexes to exit the nucleus without needing to unfold. By studying the proteins involved in this process, the research aims to uncover how this pathway is regulated and its implications for diseases like cancer. Patients may benefit from insights gained into how misregulation of this transport process contributes to tumor growth and progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers or conditions related to cellular transport abnormalities.
Not a fit: Patients with conditions unrelated to cellular transport mechanisms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating cancers and other diseases linked to cellular transport dysfunction.
How similar studies have performed: While the concept of nuclear transport is well-established, the specific mechanism of NE-budding is relatively novel and has not been extensively studied, indicating a potential for groundbreaking findings.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PARKHURST, SUSAN M — FRED HUTCHINSON CANCER CENTER
- Study coordinator: PARKHURST, SUSAN M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Aldrich Syndrome, CMV infection, Cancers